UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No. )
| Filed by the Registrant | | | ☒ | | | |
| Filed by a Party other than the Registrant | | | ☐ | | | |
Check the appropriate box:
| ☐ | | | Preliminary Proxy Statement | ||
| ☐ | | | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | ||
| ☐ | | | Definitive Proxy Statement | ||
| ☒ | | | Definitive Additional Materials | ||
| ☐ | | | Soliciting Material Pursuant to § 240.14a-12 |
| Rani Therapeutics Holdings, Inc. |
| (Name of Registrant as Specified In Its Charter) |
| |
| |
| (Name of Person(s) Filing Proxy Statement if other than the Registrant) |
Payment of Filing Fee (Check all boxes that apply):
| ☒ | | | No fee required. |
| ☐ | | | Fee paid previously with preliminary materials |
| ☐ | | | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
